On the 7th of November, the II annual Scientific and Practical Conference, “CAR-T Academy. Day + 1 of CAR-T Cell Therapy” will be held in Moscow.
The conference will be an important event highlighting key areas in the development and application of advanced innovative technologies in domestic medicine. A rich agenda will bring together researchers, doctors and experts on one platform. Both eminent and novice scientists will make presentations.
The forum will become a unique platform for sharing knowledge, making contacts and promoting research projects. Participants will be able to openly discuss key issues of immunotherapy, take part in heated discussions and gain new knowledge.
Three sections will be devoted to the latest achievements in the field of cellular technologies in the treatment of tumor diseases of the hematopoiesis system. The final section will be the scene of a heated debate between doctors and biologists, where experts will discuss the question: what determines the success of therapy: is it the therapeutic strategy or the structure of the CAR?
“Exactly a year ago, we announced the creation of a domestic CAR-T-cell drug. A lot of things have happened since that time. The NMRC for Hematology has received a license from the Ministry of Industry and Trade for the production of gene therapy products. And now, we are on the threshold of clinical trials, registration and production of the drug for the needs of patients with tumor diseases of the blood system. That is why it is now necessary to start training doctors on how to use CAR-T therapy, as this promising treatment method will soon become part of routine clinical practice,” said Elena Parovichnikova, General Director of the NMRC for Hematology of the Ministry of Health of the Russian Federation.
“The conference will provide a space for an in-depth dialogue. We will discuss the possibilities of production and application of CAR-T in Russia. We will answer the questions: ‘What happened?’, ‘What is being done today?’ and ‘What will happen?’. We are focused not on reviewing global trends, but on the real experience and expectations of domestic hematology,” said Apollinaria Bogolyubova-Kuznetsova, Head of the Laboratory of Transplantation Immunology of the NMRC for Hematology of the Ministry of Health of the Russian Federation.
A recent trend in cell therapy is an attempt to integrate CAR-T therapy into the overall treatment strategy of each individual patient. The conference will discuss the challenges and features of CAR-T therapy in the treatment of leukemia and lymphoma. Experts will share their experience in the development and testing of CAR-T cells.
The conference will be held in a hybrid format, which will allow participants to discuss the most important issues in the field of cell therapy both face-to-face and remotely. The conference is organized by the NMRC for Hematology of the Ministry of Health of the Russian Federation and the National Hematology Society with the support of industrial partners.
In order to participate in the conference, you must register. The number of places for in-person participation is limited. Registration is available on the website of the National Hematology Society at the link: https://npngo.ru/meropriyatiya/konferentsii_akademiya_car_t_den_1_car_t_kletochnoy_terapii
The conference will be broadcast live. This event will not be recorded.
Hematologists, oncologists, biologists, rheumatologists, transfusiologists, technologists, and representatives of the pharmaceutical industry interested in the topic of cell therapy are invited to participate.
Last year, the Conference “CAR-T Academy. Day 0 of CAR-T Cell Therapy” included 3 thematic sessions: development, production, and clinical application of cellular technologies, in which both significant achievements in the field and current problems arising throughout the life cycle of cellular drugs were discussed.